Abstract
Melanoma inhibitory activity (MIA) was originally identified as an 11 kDa protein secreted from malignant melanoma cells. We have shown that MIA is strongly expressed in melanoma and melanoma cell lines but not in melanocytes and normal skin. We also observed that MIA mRNA expression correlates with progressive malignancy of melanocytic tumors.
Measuring MIA in serum or plasma by a sensitive and quantitative ELISA and investigating the potential of MIA serum levels as a novel marker for malignant melanomas showed that the protein can be used to monitor therapy and follow-up. The present study measured the variations in blood concentrations of MIA in 84 patients with stage II—IV melanoma by ELISA. Patients treated with repeated injections of a polyvalent melanoma vaccine (PMV), interferon-α-2b (IFN-α2b) or interleukin-2 (IL-2) were followed during treatment duration. Before treatment, patients treated with PMV or IFN-α2b had comparable low MIA concentrations, whereas most IL-2-treated patients had higher MIA levels. At the end of treatment, MIA concentrations were higher in patients with progressive disease (PD) than in patients with no clinical evidence of melanoma (NPD) for PMV, IFN-α2b or IL-2 therapy (3.7±0.2 vs 11.5±5.4 ng/ml, 3.8±0.2 vs 8.3±1.7 ng/ml, and 2.3±0.7 vs 20.2 ± 7.4 ng/ml, respectively, p < 0.05). In contrast to the stable MIA concentrations measured in NPD patients, significant increase in MIA levels were observed in PD patients over time regardless of treatment. For PMV- and IFN-α2b-treated patients, a rise in MIA levels occurred significantly earlier than clinical diagnosis of melanoma recurrence.
In conclusion, our data suggest that quantitation of MIA serum levels may be used for detection of both clinically apparent and non-apparent metastatic melanoma disease and for monitoring therapy.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Apfel R, Lottspeich F, Hoppe J, Behl C, Durr G, Bogdahn U (1992) Purification and analysis of growth regulating proteins secreted by a human melanoma cell line. Melanoma. Res 2:327–336
Bogdahn U, Apfel R, Hahn M, Gerlach M, Behl C, Hoppe J, Martin R (1989) Autocrine tumor cell growth-inhibiting activities from human malignant melanoma. Cancer Res 49:5358–5363
Bonfrer JM, Korse CM, Nieweg OE, Rankin EM (1998) The luminescence immunoassay S-100: a sensitive test to measure circulating S-100B: its prognostic value in malignant melanoma. Br J Cancer 77:2210–2214
Bosserhoff AK, Hein R, Bogdahn U, Buettner R (1996) Structure and promoter analysis of the gene encoding the human melanoma-inhibiting protein MIA. J Biol Chem 271:490–495
Bosserhoff AK, Kaufmann M, Kaluza B, Bartke I, Zirngibl H, Hein R, Stolz W, Buettner R (1997a) Melanoma-inhibiting activity, a novel serum marker for progression of malignant melanoma. Cancer Res 57:3149–3153
Bosserhoff AK, Kondo S, Moser M, Dietz UH, Copeland NG, Gilirert DJ, Jenkins NA, Buettner R, Sandell LJ (1997b) Mouse CD-RAP/MIA gene: structure, chromosomal localization, and expression in cartilage and chondrosarcoma. Dev Dyn 208:516–525
Cochran AJ, Lu HF, Li PX, Saxton R, Wen DR (1993) S-100 protein remains a practical marker for melanocytic and other tumours. Melanoma Res 3:325–330
Cochran AJ, Wen DR (1985) S-100 protein as a marker for melanocytic and other tumours. Pathology 17:340–345
Dreau D, Foster M, Culberson C, Holder WDJ (1997) Specific IgG immune responses in melanoma patients treated with cell-vaccine. Proc Am Assoc Cancer Res 38:396
Fusi S, Ariyan S, Sternlicht A (1993) Data on first recurrence after treatment for malignant melanoma in a large patient population. Plast Reconstr Surg 91:94–98
Glaser R, Rass K, Seiter S, Hauschild A, Christophers E, Tilgen W (1997) Detection of circulating melanoma cells by specific amplification of tyrosinase complementary DNA is not a reliable tumor marker in melanoma patients: a clinical two-center study. J Clin Oncol 15:2818–2825
Kroiss MM, Bosserhoff AK, Vogt T, Buettner R, Bogenrieder T, Landthaler M, Stolz W (1998) Loss of expression or mutations in the p73 tumour suppressor gene are not involved in the pathogenesis of malignant melanomas. Melanoma Res 8:504–509
La Valle GJ, Williams NY, Walker MJ, Triozzi PL, Barbera-Guillem E (1998) Expression of melanoma inhibitory activitya in the peripheral blood of melanoma patients by the reverse transcriptase-polymerase chain reaction (RT-PCR). Proc Am Assoc Cancer Res 39:229
Miliotes G, Lyman GH, Cruse CW, Puleo C, Albertini PA, Rapaport D, Glass F, Fenske N, Soriano T, Cuny C, Van Voorhis N, Reintgen D (1996) Evaluation of new putative tumor markers for melanoma. Ann Surg Oncol 3:558–563
Morton DL, Barth A (1996) Vaccine therapy for malignant melanoma. CA. Cancer J Clin 46:225–244
Morton DL, Foshag LJ, Hoon DS, Nizze JA, Famatiga E, Wanek LA, Chang C, Davtyan DG, Gupta RK, Elashoff R (1992) Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine [published erratum appears in Ann Surg 1993 Mar; 217(3):309]. Ann Surg 216:463–482
Muhlbauer M, Langenbach N, Stolz W, Hein R, Landthaler M, Buettner R, Bosserhoff AK (1999) Detection of melanoma cells in the blood of melanoma patients by melanoma-inhibitory activity (MIA) reverse transcription-PCR [In Process Citation]. Clin Cancer Res 5:1099–1105
Reinhold U, Ludtke-Handjery HC, Schnautz S, Kreysel HW, Abken H (1997) The analysis of tyrosinase-specific mRNA in blood samples of melanoma patients by RT-PCR is not a useful test for metastatic tumor progression. J Invest Dermatol 108:166–169
Reintgen DS, Cruse CW, Wells KE, Saba HI, Fabri PJ (1992) The evaluation of putative tumor markers for malignant melanoma. Ann Plast Surg 28:55–59
Rossi CR, Foletto M, Vecchiato A, Alessio S, Menin N, Lise M (1997) Management of cutaneous melanoma MO: state of the art and trends [see comments]. Eur J Cancer 33:2302–2312
Sarantou T, Chi DD, Garrison DA, Conrad AJ, Schmid P, Morton DL, Hoon DS (1997) Melanoma-associated antigens as messenger RNA detection markers for melanoma. Cancer Res 57:1371–1376
Seregni E, Massaron S, Martinetti A, Illeni MT, Rovini D, Belli F, Agresti R, Greco M, Cascinelli N, Bombardieri E (1998) S-100 protein serum levels in cutaneous malignant melanoma. Oncol Rep 5:601–604
von Schoultz E, Hansson LO, Djureen E, Hansson J, Karnell R, Nilsson B, Stigbrand T, Ringborg U (1996) Prognostic value of serum analyses of S-100 beta protein in malignant melanoma. Melanoma Res 6:133–137
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2001 Springer-Verlag Berlin · Heidelberg
About this paper
Cite this paper
Bosserhoff, A.K., Dreau, D., Hein, R., Landthaler, M., Holder, W.D., Buettner, R. (2001). Melanoma Inhibitory Activity (MIA), a Serological Marker of Malignant Melanoma. In: Reinhold, U., Tilgen, W. (eds) Minimal Residual Disease in Melanoma. Recent Results in Cancer Research, vol 158. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-59537-0_16
Download citation
DOI: https://doi.org/10.1007/978-3-642-59537-0_16
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-64015-5
Online ISBN: 978-3-642-59537-0
eBook Packages: Springer Book Archive